AOD-9604 vs CJC-1295

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

AOD-9604 (anti-obesity drug 9604; Tyr-hGH(177–191)) is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone, modified with an N-terminal tyrosine residue for stability, and investigated as a candidate anti-obesity compound on the premise that the lipolytic activity of hGH resides in this C-terminal domain — separable from the growth-promoting and insulin-antagonizing effects mediated by other regions of the full-length molecule. AOD-9604 is proposed to stimulate fat metabolism through beta-3 adrenergic receptor-mediated pathways without activating IGF-1 production or the anabolic receptor domains of full-length GH, making it theoretically safer than GH itself for metabolic applications; preclinical studies in obese mice demonstrated lipolytic effects and body weight reduction. Clinical trials were conducted in humans by Metabolic Pharmaceuticals, and Phase 2/3 data generated in Australia suggested modest weight loss effects; however, the primary trial results were never published in PubMed-indexed peer-reviewed journals, and the best indexed primary evidence for AOD-9604 remains a preclinical study in obese mice demonstrating effects on lipid metabolism. AOD-9604 has no FDA approval and no approved indication in any jurisdiction; despite its human clinical program, the absence of published peer-reviewed primary trial data means clinical efficacy and safety cannot be independently evaluated, and the compound is currently available only as a research peptide. AOD-9604 is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before subcutaneous administration; the volume of BAC water added to the vial determines the concentration of the resulting solution, following standard peptide reconstitution methodology. Research on AOD-9604 peptide dosage was conducted in both the preclinical obese-mouse model and the Phase 2/3 human clinical program in adult obesity populations; clinical trial dosage data exists from the Metabolic Pharmaceuticals program, though primary results were not published in indexed peer-reviewed journals. Oral formulations of AOD-9604 were also evaluated in the clinical program as an alternative to subcutaneous delivery. AOD-9604 dosage context In the Metabolic Pharmaceuticals clinical program, AOD-9604 was evaluated at oral doses of 1mg and 9mg daily, and via subcutaneous injection at approximately 1mg/day in Phase 2/3 human obesity studies. In the research peptide community, subcutaneous protocols commonly reference 250–300mcg once daily, administered to the subcutaneous adipose tissue of the abdomen. These figures derive from the research context rather than an approved clinical protocol — AOD-9604 has no approved dosing for any human indication. Reconstitution follows standard peptide preparation: a 5mg vial combined with 2mL bacteriostatic water yields 2,500mcg/mL (0.1mL = 250mcg per injection). Oral formulations were evaluated in the clinical trial as a potential non-injectable route; no commercial oral AOD-9604 product exists. AOD-9604 side effects and safety profile The safety data from AOD-9604's clinical program includes several notable findings: no elevation in IGF-1 levels was observed at studied doses — a key distinction from full-length growth hormone, where IGF-1 elevation drives concerns about cell proliferation and potential oncogenicity. No significant disruption of fasting glucose or insulin sensitivity was documented. No serious adverse events attributable to AOD-9604 were reported in published trial summaries. The absence of anabolic receptor activity (no binding to the GH receptor growth-promoting domain) is the proposed basis for this benign safety profile compared to GH itself. Long-term safety data does not exist due to the absence of Phase 3 completion and product approval. Research-grade AOD-9604 carries standard purity and contamination risks associated with unregulated compounding. Providers offering AOD-9604 through supervised clinical programs are searchable in the PeptideBase provider directory.

CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.

CJC-1295 (DAC-GRF) is a synthetic 30-amino-acid GHRH analog incorporating a Drug Affinity Complex (DAC) modification — trans-4-aminomethylcyclohexane carboxylic acid — that enables covalent binding to circulating albumin, dramatically extending the plasma half-life from minutes (as with native GHRH) to approximately 6–8 days and enabling once or twice-weekly dosing for sustained GH and IGF-1 elevation. The extended half-life allows CJC-1295 to act as a continuous GHRH-receptor agonist at pituitary somatotrophs rather than producing pulsatile stimulation, stimulating cumulative GH secretion and downstream IGF-1 production; this pharmacokinetic profile distinguishes it from short-acting GHRH analogs such as sermorelin and positions it for research in GH axis restoration. A Phase 1 dose-escalation RCT in healthy adults published in the Journal of Clinical Endocrinology and Metabolism (2006) demonstrated dose-dependent and sustained increases in mean GH and IGF-1 concentrations following single-dose administration, establishing the only indexed human pharmacokinetic and pharmacodynamic data for this compound; all other indexed literature consists of anti-doping detection methods. CJC-1295 has no FDA approval and no approved therapeutic indication in any jurisdiction; it is available only as a research compound and the clinical evidence base is limited to a single Phase 1 safety and PK study in healthy subjects, with no Phase 2 or Phase 3 data addressing efficacy for any specific indication. CJC-1295 and ipamorelin combination: CJC-1295 is most commonly studied in combination with ipamorelin, a selective GHRP (growth hormone-releasing peptide), because the two compounds act on complementary pathways to stimulate GH release. CJC-1295 activates the GHRH receptor at pituitary somatotrophs, providing a sustained permissive signal for GH secretion; ipamorelin activates the ghrelin receptor (GHS-R1a), producing a discrete GH pulse with high selectivity and without meaningfully elevating cortisol or prolactin. Research and clinical interest in the combination centers on the synergistic GH pulse amplitude achieved when both pathways are stimulated together — greater than either compound alone. The pharmacokinetic profiles are complementary: CJC-1295's extended half-life (6–8 days) provides a stable GHRH background, while ipamorelin's short half-life (approximately 2 hours) allows timed pulsatile stimulation. In clinical research contexts, CJC-1295 is typically administered subcutaneously one to two times weekly to maintain a sustained GH baseline, while ipamorelin is dosed more frequently — daily or multiple times per day — to generate GH pulses aligned with sleep or exercise. A triple-stack combining CJC-1295, ipamorelin, and sermorelin is referenced in some clinical contexts for additive GH axis stimulation, though evidence supporting the triple combination beyond individual compound data is limited. All dosing references are for research contexts only; no approved clinical protocols exist for any of these combinations. Subcutaneous vs intramuscular injection for CJC-1295: CJC-1295 is administered exclusively via subcutaneous injection in all published research — intramuscular injection is not used for this compound. Subcutaneous injection into abdominal fat or thigh tissue results in slower, more consistent absorption suitable for the depot-like pharmacokinetic profile that CJC-1295's DAC modification already provides. Rotation of injection sites is recommended to avoid lipohypertrophy at repeated injection locations. Injection technique, site preparation with an alcohol swab, and proper needle gauge selection (typically 27–31G for subcutaneous peptide injection) are standard considerations across all subcutaneous peptide administration contexts.